Amitriptilina

證據等級: L5

預測適應症: 0 個

Amitriptyline (AMITRIPTILINA): Drug Repurposing Evaluation Report

One-Sentence Summary

Amitriptyline (AMITRIPTILINA) is a well-known tricyclic antidepressant widely used for depression, neuropathic pain, and migraine prophylaxis. The TxGNN model did not generate any predicted new indications for this compound in the current analysis cycle. Significant data gaps remain, including mechanism of action details, regulatory safety information, and market authorization data for Italy.

Quick Overview

Item	Content
Drug (INN)	AMITRIPTILINA (Amitriptyline)
DrugBank ID	Not available
Original Indication	Not recorded in evidence pack (known: depression, neuropathic pain)
Predicted New Indication	None — no indications predicted by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions and no supporting studies in this pack
Italy Market Status	❌ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

There is no TxGNN prediction to evaluate for Amitriptyline in this analysis cycle. The predicted indications list is empty, meaning the model either did not process this drug or did not identify indications meeting the confidence threshold.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Amitriptyline is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of serotonin and norepinephrine. It also has anticholinergic, antihistaminic, and sodium channel–blocking properties, which account for its broad clinical utility in depression, neuropathic pain, migraine prophylaxis, and functional gastrointestinal disorders. However, none of this mechanistic rationale can be linked to a new predicted indication because no prediction was generated.

Before a meaningful evaluation can be performed, the TxGNN prediction pipeline should be re-run for Amitriptyline to determine if any repurposing candidates emerge. The drug's rich polypharmacology makes it a plausible candidate for multi-target repurposing once data gaps are resolved.

Clinical Trial Evidence

Currently no related clinical trials registered in this evidence pack — no predicted indication was available to query against.

Literature Evidence

Currently no related literature available in this evidence pack — no predicted indication was available to query against.

Italy Market Information

No marketing authorizations recorded. Amitriptyline does not appear to hold current AIFA-approved licenses in the dataset reviewed (0 licenses found).

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug-drug interactions) returned no data in the current evidence pack. The DDI query returned not_found with 0 interactions. This represents a Blocking data gap (DG001) that must be resolved before any Stage 1 safety assessment can proceed.

Data Gaps Summary

The following critical gaps were identified and should be addressed before re-evaluation:

Gap ID	Category	Item	Severity	Remediation
DG001	Drug Level	Package insert warnings / contraindications	Blocking	Download and parse package insert PDF from regulatory authority website
DG002	Drug Level	Mechanism of Action (MOA)	High	Query DrugBank API (note: DrugBank ID is currently missing)
—	Prediction	TxGNN predicted indications	Blocking	Re-run TxGNN prediction pipeline for Amitriptyline
—	Drug Level	DrugBank ID	High	Resolve DrugBank mapping (DB00321 is the known ID for Amitriptyline)
—	Regulatory	Italy market authorization data	Medium	Query AIFA database directly

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN prediction was generated for Amitriptyline, and multiple blocking data gaps (safety information, MOA, regulatory data) prevent any meaningful repurposing evaluation. The evidence pack is essentially empty across all key dimensions.

To proceed, the following is needed:

Resolve DrugBank mapping — Amitriptyline's known DrugBank ID is DB00321; linking this would unlock MOA, toxicity, and interaction data
Re-run TxGNN prediction pipeline with corrected drug identifier to generate candidate indications
Obtain AIFA / regulatory safety data — download and parse the package insert to fill the blocking DG001 gap
Re-query DDI databases once DrugBank ID is properly linked
Re-generate evidence pack after the above gaps are filled, then re-evaluate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.